* Overall solid report; focus turning to capital allocation * We cut '26e-'27e adj.
Taaleri's Q4 results came in clearly above our expectations, owing to good performance in all key op...
Redeye comments on Vertiseit’s Q4 report showing somewhat lower organic ARR growth and higher OPEX t...
Careium continued to grow organically in the quarter.
* Margin pressure to remain in H1'26e * We cut our '26-'27 EBIT estimates by 15% and 9% * Share is t...
Siili is shaping itself to benefit from the structural market change over time.
Kalqyl och FairValue presenterar nu en samlad genomgång av sex bolag med lönsamhetsförbättringar i s...
* Q4 boosted by Valuation France divestment * We cut 2026e-27e EBIT by 6-8% * 2025e-27e EV/EBIT of 4...
Redeye presents its preview for Senzime’s Q4 2025 report, due on February 18.
Finnair’s EUR 789.5m Q4 revenue was quite close to estimates, but the EUR 61.
* Q4 sales 4% above our ests. at SEK 231m, for 6% org.
Redeye retains its positive view of CombinedX following the Q4 report.
* We keep our estimates unchanged... * ...and expect ~10-11% adj.
NoHo Partners reported Q4 EBIT of EUR 11.8m (-3.7% y/y), 4% above Vara Research consensus and 6% abo...
Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat o...
Taaleri’s Q4 2025 continuing earnings of EUR 12.2m increased by 17% y/y and came 18% above our estim...
Siili's Q4 sales missed our estimate by 7% as domestic operations saw a clear decline and overall th...
Nelly delivered a decent Q4 report in our view with c.
Redeye provides a research update after Optomed’s Q4 2025 report.
Redeye updates its view following CTEK’s Q4 report.
